Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 350 of 2873 entries
View as:

Study of Erlotinib in Combination With Bortezomib

Phase: N/A Priority: Normal
NCT ID: NCT00895687 Org: User:
Start: 04/30/09 End: - Due: -

Irinotecan Plus Brivanib in Metastatic Colorectal Cancer (CRC) Enriched for Elevated Levels of Plasma FGF

Phase: N/A Priority: Normal
NCT ID: NCT01367275 Org: User:
Start: 08/31/11 End: 11/30/13 Due: 11/30/14

Gastrointestinal Stromal Tumors (GIST) Registry

Phase: N/A Priority: Normal
NCT ID: NCT00507273 Org: User:
Start: 08/31/05 End: 12/31/10 Due: 12/31/11

NBTXR3 and Radiation Therapy for the Treatment of Inoperable Recurrent Non-small Cell Lung Cancer

Phase: N/A Priority: Normal
NCT ID: NCT04505267 Org: User:
Start: 02/10/21 End: 03/31/26 Due: 03/31/27

Inflammatory Response and Tissue Fibrosis/ Lymphatico-venous Bypass

Phase: N/A Priority: Normal
NCT ID: NCT01433302 Org: User:
Start: 03/31/12 End: 03/31/14 Due: 03/31/15

A Phase II, Single-Arm Study of RAD001 (Everolimus), Letrozole, and Metformin in Patients With Advanced or Recurrent Endometrial Carcinoma

Phase: N/A Priority: Normal
NCT ID: NCT01797523 Org: User:
Start: 10/07/13 End: 10/31/25 Due: 10/31/26

Letrozole and RAD001 With Advanced or Recurrent Endometrial Cancer

Phase: N/A Priority: Normal
NCT ID: NCT01068249 Org: User:
Start: 04/30/10 End: 04/30/28 Due: 04/30/29

The Phoenix Trial: Phase II Trial of Cemiplimab for the Non-operative Management of Localized dMMR Colon Cancer

Phase: N/A Priority: Normal
NCT ID: NCT05961709 Org: User:
Start: 05/20/24 End: 04/30/28 Due: 04/30/29

Efficacy of the Third Eye Retroscope Auxiliary Imaging System

Phase: N/A Priority: Normal
NCT ID: NCT00657371 Org: User:
Start: 03/31/08 End: 05/31/10 Due: 05/31/11

Alisertib and Pembrolizumab for the Treatment of Patients With Rb-deficient Head and Neck Squamous Cell Cancer

Phase: N/A Priority: Normal
NCT ID: NCT04555837 Org: User:
Start: 09/15/20 End: 04/08/25 Due: 04/08/26

Prebiotic Food-enriched Diet (PreFED) to Enhance the Microbiome and Response to First-line Immunotherapy in Unresectable Melanoma

Phase: N/A Priority: Normal
NCT ID: NCT06466434 Org: User:
Start: 09/04/24 End: 06/30/29 Due: 06/30/30

Study of CAR.70-engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Advanced Renal Cell Carcinoma, Mesothelioma and Osteosarcoma

Phase: N/A Priority: Normal
NCT ID: NCT05703854 Org: User:
Start: 03/29/23 End: 09/30/27 Due: 09/30/28

Neratinib and Capmatinib Combination (Phase Ib/II) in Metastatic Breast Cancer and Inflammatory Breast Cancer Patients With Abnormal HER-family and c-Met Pathway Activity as Measured by the CELsignia Signaling Analysis Test

Phase: N/A Priority: Normal
NCT ID: NCT05243641 Org: User:
Start: 08/18/22 End: 11/19/24 Due: 11/19/25

A Phase II Study of Loncastuximab Tesirine as Consolidation Strategy in Patients With LBCL in PR After CAR T-cell Therapy

Phase: N/A Priority: Normal
NCT ID: NCT05464719 Org: User:
Start: 09/23/22 End: 01/30/26 Due: 01/30/27

Tagraxofusp in Treating Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm After Stem Cell Transplant

Phase: N/A Priority: Normal
NCT ID: NCT04317781 Org: User:
Start: 03/27/20 End: 07/11/23 Due: 07/11/24

Venetoclax With Ibrutinib or Acalabrutinib in Pts. With High-risk CLL

Phase: N/A Priority: Normal
NCT ID: NCT03128879 Org: User:
Start: 06/16/17 End: 05/31/27 Due: 05/31/28

An Endometrial Cancer Chemoprevention Study of Metformin

Phase: N/A Priority: Normal
NCT ID: NCT01697566 Org: User:
Start: 05/30/13 End: 05/30/24 Due: 05/30/25

Infusion of Expanded Cord Blood T Cells

Phase: N/A Priority: Normal
NCT ID: NCT00972101 Org: User:
Start: 09/30/09 End: 09/30/11 Due: 09/30/12

Trial Of PreoperAtive Radiation (TOPAz): A Randomized Trial Comparing Hypofractionated Versus Conventionally Fractionated Preoperative Radiation Followed by Mastectomy With Immediate Autologous Breast Reconstruction With Integrated Nanomechanical Biomarker Evaluation

Phase: N/A Priority: Normal
NCT ID: NCT05774678 Org: User:
Start: 04/05/23 End: 11/01/28 Due: 11/01/29

Phase Ib Trial of the KRAS G12C Inhibitor Adagrasib (MRTX849) in Combination With the PARP Inhibitor Olaparib in Patients With KRAS G12C Mutated Advanced Solid Tumors, With a Focus on Gynecological, Breast, Pancreatic and KEAP1 Mutated Non-small Cell Lung Cancers

Phase: N/A Priority: Normal
NCT ID: NCT06130254 Org: User:
Start: 01/30/24 End: 08/25/30 Due: 08/25/31

Osimertinib, Surgery, and Radiation Therapy in Treating Patients With Stage IIIB or IV Non-small Cell Lung Cancer With EGFR Mutations, NORTHSTAR Study

Phase: N/A Priority: Normal
NCT ID: NCT03410043 Org: User:
Start: 01/17/18 End: 04/01/26 Due: 04/01/27

Health Benefits of Writing Therapy Among Asian American Cancer Survivors

Phase: N/A Priority: Normal
NCT ID: NCT06367959 Org: User:
Start: 07/27/23 End: 08/31/26 Due: 08/31/27

A Study of the ApricityCare Program for Early Detection and Management of Treatment-Related Adverse Events in Patients With Cancer

Phase: N/A Priority: Normal
NCT ID: NCT06693687 Org: User:
Start: 12/18/24 End: 11/01/27 Due: 11/01/28

Hyper-CVAD With Liposomal Vincristine in Acute Lymphoblastic Leukemia

Phase: N/A Priority: Normal
NCT ID: NCT01319981 Org: User:
Start: 03/05/13 End: 11/11/20 Due: 11/11/21

TK216 and Decitabine in Treating Patients With Relapsed and Refractory Acute Myeloid Leukemia

Phase: N/A Priority: Normal
NCT ID: NCT03752138 Org: User:
Start: 03/31/19 End: 12/31/20 Due: 12/31/21